返回 Agendas
Emerging Practices in Product Commercialization Planning: How Cross Collaboration Is Redefining Product Development Planning
Session Chair(s)
Alberto Grignolo, PhD
Editor-in-Chief
DIA Global Forum, United States
Economic pressures on drug pricing/reimbursement require that companies plan market access early in development, promote clinical/regulatory/commercial collaboration and execute the right studies to provide evidence to both regulators and payers.
Learning Objective : Identify what issues need to be addressed during drug development in order to optimize pricing and reimbursement; Describe how market access departments collaborate with clinical and regulatory throughout the drug development process to prepare for successful launch and commercialization after obtaining regulatory approval; Assess the pros/cons and best practices of this collaboration.
Speaker(s)
Integrating Proof of Concept and Proof of Value in Early Development
Cyril P Clarke, MD
ICON, United Kingdom
Vice President, Translational Medicine
Registration and Reimbursement Strategies in Drug Development: Merging Constructs to Maximize Return on Invested Capital
Richard Williams, JD, PhD
Covance Inc., United States
Regulatory Strategy
How Industry Pursues Internal and External Cross-Functional Collaborations During Drug Development to Optimize Market Access After Regulatory Approval
Schiffon Wong, MPH
EMD Serono, United States
Executive Director, Global Evidence and Value Development, Global R&D
注册方法
Registration override should work.